Drug Safety Monitor Download
Safety Comparison of Viekira Pak, the Newly Approved Chronic Genotype 1 Hepatitis C Treatment
This report compares the prescribing information of Viekira Pak and Harvoni, and on-label adverse events of Viekira Pak to the post-marketing case reports of Sovaldi. We employed our proprietary RxFilter to determine Sovaldi’s ROR values for on-label Sovaldi adverse events (AEs), discussed off-label AEs for Sovaldi that may trigger future pharmacovigilance signals via RxSignal, and compared RxScores among Chronic Hepatitis C treatments.
Drugs Covered: HARVONI, SOVALDI, VIEKIRA PAK
Drug Classes Covered: Other antivirals
Indications Covered: Chronic Hepatitis C
Mechanism of Action Covered: Cytochrome P450 2C19 Inducers, Cytochrome P450 2D6 Inhibitors, Cytochrome P450 3A Inhibitors, Enzyme Inhibitors, HCV NS3/4A Protease Inhibitors, HCV NS5A Inhibitor, HCV Nucleotide Analog NS5B Polymerase Inhibitor, HIV Protease Inhibitors, Nucleic Acid Synthesis Inhibitors, P-Glycoprotein Inhibitors